Opus Genetics is trading 5.1% up at $4.74 in pre-market on October 2, with the reason for the rise unclear. - The investor-relations press-release page lists September 9 as the latest release; no new October 1 or October 2 company-specific catalyst surfaced. - Biotech ETF XBI was down 2.01% pre-market, which does not explain the stock’s gain.